Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mark Grier"'
Autor:
Mark Grier, Mark L. Nelson, Viollandi Prifti, Marc W. Halterman, Nguyen Mai, Kathleen Miller-Rhodes, Max H. Sims, Sara A. Knowlden
Publikováno v:
Exp Mol Pathol
Cerebral ischemia triggers a cascade of neuroinflammatory and peripheral immune responses that contribute to post-ischemic reperfusion injury. Prior work conducted in CNS ischemia models underscore the potential to harness non-antibiotic properties o
Autor:
Mark Grier, Michael Draper, Caroline Dudley, Peter J. Donovan, Oak K. Kim, Kevin A. Klausner, Victoria J. Bartlett, S. Ken Tanaka, Michael N. Alekshun, Stuart B. Levy, Lynne Garrity-Ryan
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:3380-3383
ExsA is a multiple adaptational response (MAR) transcription factor, regulating the expression of a virulence determinant, the type III secretion system (T3SS) in Pseudomonas aeruginosa. Non-cytotoxic, non-antibacterial N-hydroxybenzimidazoles were i
Autor:
Michael N. Alekshun, Ann B. Macone, Atul K. Verma, S. Ken Tanaka, Mark Grier, Victoria J. Bartlett, Oak K. Kim, J. Donatelli, Lynne Garrity-Ryan, Stuart B. Levy, Gabriel Medjanis
Publikováno v:
Journal of Medicinal Chemistry. 52:5626-5634
LcrF, a Multiple Adaptational Response (MAR) transcription factor, regulates virulence in Yersinia pestis and Yersinia pseudotuberculosis. In a search for small molecule inhibitors of LcrF, an acrylic amide series of N-hydroxybenzimidazoles was synth
Publikováno v:
Anti-Infective Agents in Medicinal Chemistry. 8:3-16
Autor:
Mark Grier, Michael N. Alekshun, Atul K. Verma, Victoria J. Bartlett, Todd Bowser, Taduesz Warchol, Stuart B. Levy
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:5652-5655
Structure-based drug design was utilized to identify potent small-molecule inhibitors of proteins within the AraC family of bacterial transcription factors, which control virulence in medically important microbes. These agents represent a novel appro
Autor:
Caroline E, Bass, Graeme, Griffin, Mark, Grier, Anu, Mahadevan, Raj K, Razdan, Billy R, Martin
Publikováno v:
Pharmacology, biochemistry, and behavior. 74(1)
The central cannabinoid receptor (CB(1)) antagonist, SR-141716A, has been used extensively to ascertain that cannabinoids interact with the CB(1) receptor. SR-141716A has been shown to produce effects opposite of cannabinoids when administered alone.